Today: 9 June 2026
Lionsgate Studios (LION) stock slides today after insider sales hit the tape
30 December 2025
1 min read

Lionsgate Studios (LION) stock slides today after insider sales hit the tape

NEW YORK, December 30, 2025, 13:49 ET — Regular session

  • Lionsgate Studios shares fell about 3.4% in Tuesday trading, lagging most media peers.
  • SEC filings showed CEO Jon Feltheimer and Vice Chair Michael Burns sold shares in late December, citing year-end tax planning.
  • Traders are watching whether the stock holds the $9 level after a run toward the top of its 52-week range.

Lionsgate Studios Corp shares fell 3.4% on Tuesday, retreating after filings showed two top executives sold stock late this month. The stock was down 32.5 cents at $9.105, after trading between $9.06 and $9.45.

The disclosures landed with the stock near the top of its 52-week range of $5.55 to $9.46. That has made the name more sensitive to any sign of selling pressure heading into year-end.

Form 4 filings — mandatory SEC reports that disclose insider buying and selling — can move shares in the short term because they add supply and offer a window into executive behavior. At year-end, those sales often relate to taxes tied to vesting stock awards.

Chief Executive Officer Jon Feltheimer sold 195,000 common shares on Dec. 22 at a weighted average price of $8.28, a Form 4 filing showed. The filing said the transactions were “effected solely for year-end tax planning purposes.” SEC

Vice Chair Michael Burns sold 21,748 common shares on Dec. 23 at a weighted average price of $9.01, according to a separate Form 4. Burns reported beneficial ownership of more than 3 million shares after the sale, a figure that includes restricted stock units, or RSUs — stock awards that convert into common shares as they vest.

The broader market was mostly steady, leaving Lionsgate’s move to stand out as largely stock-specific. The S&P 500 tracker SPY and Nasdaq 100 tracker QQQ were both little changed.

Media and streaming stocks were mixed. Walt Disney was up about 0.9% and Warner Bros. Discovery added about 0.5%, while Netflix dipped about 0.4%.

Investors often treat tax-driven insider sales as a neutral signal, especially when executives retain large positions. But repeated Form 4 headlines can still weigh on the tape, particularly when a stock is near a 52-week high and momentum traders are active.

Lionsgate Studios is the film and television studio behind franchises including “The Hunger Games” and “John Wick,” after Lionsgate moved to separate its studio operations from its Starz business in prior corporate actions. Reuters

The next major catalyst is earnings. Zacks’ earnings calendar lists Lionsgate Studios’ next report for Feb. 5, 2026, keeping attention on any update to the studio’s revenue outlook and path to profitability.

On valuation, Stock Analysis data show analysts’ average price target sits around $9.11, roughly in line with where the stock traded midday Tuesday.

Stock Market Today

  • Semiconductor Stock Poised to Surpass Micron Technology by 2028
    June 9, 2026, 10:18 AM EDT. Micron Technology has surged nearly 800% recently, driven by high demand and pricing power in memory chips, pushing its market cap past $1 trillion. However, analysts predict supply constraints easing by 2028 could cause earnings to peak and decline, potentially halving share value to around $517.50. Meanwhile, a major semiconductor competitor valued around $650 billion is expanding production, potentially surpassing Micron's value by 2028. The industry faces cyclical dynamics as new manufacturing capacity comes online globally, impacting pricing and earnings. Investors are watching these shifts closely for long-term positioning amid evolving chip supply and demand.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next
Previous Story

SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next

Newmont stock rebounds as gold steadies after CME margin jolt; Raymond James lifts target
Next Story

Newmont stock rebounds as gold steadies after CME margin jolt; Raymond James lifts target

Go toTop